Natco Pharma

Natco Pharma (India) holds 54 active US FDA Type II Drug Master Files and 11 inactive, has DMF or CEP filings on record for 40 active ingredients and is linked to 3 FDA-registered manufacturing sites. 16 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Natco Pharma: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/natco-pharma

Overview

Natco Pharma is a leading pharmaceutical company based in India, specializing in the development and manufacturing of pharmaceutical products. The company is renowned for its focus on research and development in the area of generic and specialty medicines.

Core services & business areas

ManufacturingResearch and DevelopmentRegulatory AffairsMarketing and Distribution

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Natco Pharma holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Natco Pharma holds 54 active (65 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • TUCATINIBActive2026-09-30
  • DEUCRAVACITINIBActive2026-07-02
  • IMATINIB MESYLATE ß FORMActive2026-05-18
  • NUSINERSEN SODIUMActive2026-03-25
  • RUXOLITINIB PHOSPHATEActive2026-01-13
  • VENETOCLAXActive2024-11-15
  • RISDIPLAMActive2024-04-30
  • LURBINECTEDINActive2024-03-25
  • CAPMATINIB HYDROCHLORIDEActive2024-03-21
  • CIDOFOVIR DIHYDRATE USPActive2023-08-23
  • NILOTINIB HYDROCHLORIDE MONOHYDRATEActive2022-12-02
  • ALECTINIB HYDROCHLORIDEActive2022-03-25
  • CABOZANTINIB (S)-MALATEActive2022-02-28
  • ERIBULIN MESYLATEActive2022-01-06
  • IDELALISIBActive2021-11-18
  • ACALABRUTINIB DIHYDRATEActive2021-09-15
  • CARMUSTINEActive2020-03-03
  • TRIFLURIDINEActive2019-08-08
  • TIPIRACIL HYDROCHLORIDEActive2019-08-08
  • SUGAMMADEX SODIUMActive2019-07-08
  • CHLOROQUINE PHOSPHATEActive2019-02-20
  • IBRUTINIB (IBN)Active2018-08-17
  • GEFITINIBActive2018-07-24
  • THIOTEPAActive2017-05-05
  • POMALIDOMIDEActive2016-11-10
  • APIXABANActive2016-09-30
  • TERIFLUNOMIDEActive2016-04-29
  • EVEROLIMUSActive2015-09-30
  • SORAFENIB TOSYLATEActive2012-12-21
  • BENDAMUSTINE HYDROCHLORIDEActive2012-12-18
  • BORTEZOMIBActive2012-12-06
  • IBANDRONATE SODIUM MONOHYDRATE (INJECTABLE GRADE)Active2011-05-31
  • LANSOPRAZOLEActive2010-02-12
  • LETROZOLE (LER)Active2009-05-29
  • RIZATRIPTAN BENZOATE (ROUTE - 2; PRODUCT CODE: RTB)Active2009-05-08
  • TRIHEXYPHENIDYL HYDROCHLORIDEActive2009-02-26
  • LANTHANUM CARBONATE DIHYDRATEActive2008-10-02
  • ERLOTINIB HYDROCHLORIDEActive2008-07-11
  • ZOLMITRIPTANActive2008-02-05
  • OMEPRAZOLEActive2008-02-05
  • SUMATRIPTAN SUCCINATE (INJECTABLE GRADE)Active2007-10-01
  • RIZATRIPTAN BENZOATEActive2007-08-21
  • GRANISETRON HYDROCHLORIDE (INJECTABLE GRADE)Active2007-07-13
  • ONDANSETRON HYDROCHLORIDE (INJECTABLE GRADE)Active2007-07-12
  • IBANDRONATE SODIUM MONOHYDRATEActive2007-04-05
  • IMATINIB MESYLATE (ALPHA 2-FORM)Active2007-04-05
  • ANASTROZOLEActive2006-08-11
  • ZOLEDRONIC ACIDActive2006-06-15
  • GRANISETRON HYDROCHLORIDEActive2006-03-03
  • LETROZOLEActive2005-06-03

Showing the 50 most relevant of 65 Drug Master Files (active first). The full list is in the FDA DMF list.

Registered manufacturing sites (3)

Physical sites registered with the US FDA and resolved to Natco Pharma, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

16 FDA enforcement records linked to this company.

  • 4832025-06-19

    Cleaning / Sanitizing / Maintenance

  • 4832025-06-19

    Buildings of Suitable Size, Construction, Location

  • 4832025-06-19

    Investigations of discrepancies, failures

  • 4832025-06-19

    Procedures for sterile drug products

  • 4832025-06-19

    Validation lacking for sterile drug products

  • 4832025-06-19

    Procedures not in writing, fully followed

  • 4832025-06-19

    Environmental Monitoring System

  • recall — Class II2024-04-17

    CGMP Deviations

  • warning_letter2024-04-08

    FDA Warning Letter (drug product)

  • recall — Class II2024-02-14

    CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules with holes and spheres sticking to capsules. Also coding details were missing on one bottle.

  • 4832017-01-24

    Written program not followed

  • 4832017-01-24

    Procedures for sterile drug products

  • 4832017-01-24

    Mix-up

  • 4832017-01-24

    Scientifically sound laboratory controls

  • 4832017-01-24

    Procedures not in writing, fully followed

  • 4832017-01-24

    Released Drug Products Area

For suppliers

Is this Natco Pharma?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.